Risk factors associated with the histological grade of canine mast cell tumor based on Kiupel’s two-tier classification of malignancy
DOI:
https://doi.org/10.17533/udea.rccp.e359535Keywords:
age, breed, canine, histologic grade, Kiupel’s classification, mast cell tumor, prognosis, risk factors, sex, skinAbstract
Background: mast cell tumor (MCT) is one of the most common neoplasms in canines, and histological grading is crucial for its prognosis. However, there is limited local information on the influence of factors such as sex, age, breed, and anatomical location of the lesion on the malignancy grade of this neoplasm. These factors are important for risk assessment and understanding the biological behavior of the tumor. Objective: to assess the association between risk factors (sex, age, breed, anatomical location) and histological grade of MCTs diagnosed at the Animal Pathology Laboratory of the Universidad de Antioquia between 2019 and 2023. Methods: retrospective study based on histopathology reports of canine biopsies; filtering patients diagnosed with MCT. Data on year of report, dog, and tumor characteristics were extracted. Descriptive statistics were presented as relative frequencies, 95% confidence intervals (CI), and Z-tests and Chi-square tests were used to identify differences between proportions. Results: 409 cases of canine MCT were analyzed, of which 74.8% were low grade (LG) and 25.2% high grade (HG). Females presented a higher frequency of high grade MCT (HG-MCT) (50.5%), with no significant differences by sex (p>0.05). Patients aged 5 to 8 years showed greater predisposition to low grade MCT (LG-MCT), while those aged 9 to 16 years to HG-MCT (p<0.05). The Bulldog and French Bulldog breeds had a greater predisposition to HG-MCT (p<0.05) and the Pitbull, Mixed-breed and Pug, were the most frequently associated with the development of MCT, without predisposition to a specific histological grade. The most common location was the trunk, with 20.4% of cases of HG-MCT and 18.6% of LG-MCT, with no significant differences (p>0.05). Conclusions: the findings highlight the relevance of age and breed in the diagnosis and management of MCT. Dogs of certain breeds and ages may be more likely to be susceptible to more aggressive forms of the tumor, which is relevant for clinical management and early risk identification.
Downloads
References
Cano-Botero A, Zapata-Cardona J, Agudelo-Quintero J, Quintana-Diosa LE. Morfología, Fisiología y Patología: Frecuencia de mastocitomas caninos diagnosticados mediante histopatología en el Laboratorio de Patología Animal de la Universidad de Antioquia - UdeA. Rev Colomb Cienc Pecu. 2024;37(Supl):216–230. https://revistas.udea.edu.co/index.php/rccp/article/view/356631/20813740
Cubillos García PA, Gutiérrez Moreno TM. Algunas generalidades sobre tumores de células redondas en perros [trabajo de grado pregrado]. Villavicencio: Universidad Cooperativa de Colombia, Facultad de Ciencias de la Salud, Medicina Veterinaria y Zootecnia; 2021. https://repository.ucc.edu.co/entities/publication/0055f93a-99bf-464e-8f4d-74b4b9283bc0
Hahn K, Ogilvie G, Rusk T, Devauchelle P, Leblanc A, Legendre A et al. Masitinib is safe and effective for treating canine mast cell tumors. J Vet Intern Med. 2008;22(6):1301-1309.https://doi.org/10.1111/j.1939-1676.2008.0190.x
Jaramillo Burneo MJ. Estudio Retrospectivo de Mastocitoma Cutáneo en Perros (Canis lupus familiaris) Diagnosticado por Histopatología en el Período 2014-2018 [Tesis de maestría]. Cuenca: Universidad de Cuenca; 2019. https://dspace.ucuenca.edu.ec/items/a29e5f61-55b5-4833-a0fb-37311889a1b4
Kiupel M, Webster JD, Bailey KL, Best S, DeLay J, Detrisac CJ, et al. Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior. Vet Pathol. 2011;48(1):147–55. https://doi.org/10.1177/0300985810386469
Kiupel M, Webster JD, Miller RA, Kaneene JB. Impact of tumorr depth, tumor location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumours. J Vet Med A Physiol Pathol Clin Med. 2005;52(6):280–286. https://doi.org/10.1111/j.1439-0442.2005.00726.x
London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, Rosenberg M et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res. 2003;9(7):2755–2768. https://aacrjournals.org/clincancerres/article/9/7/2755/203586/Phase-I-Dose-Escalating-Study-of-SU11654-a-Small
Lozano D, Murcia S, Mayorga S. Frecuencia de Neoplasias de piel en caninos Remitidos a un Laboratorio de Patología Veterinaria de Bogotá: Estudio retrospectivo en el período 2015 – 2016 [trabajo de grado pregrado]. Bogotá: Universidad de Ciencias Aplicadas y Ambientales – UDCA; 2016. https://repository.udca.edu.co/entities/publication/2d0f4b29-6dc5-46dd-af70-100fae709014
Martins AL, Carvalho FF, Mesquita JR, Gärtner F, Amorim I. Analysis of risk factors for canine mast cell tumors based on the kiupel and patnaik grading system among dogs with skin tumors. Open Vet J. 2021;11(4):619–34. https://doi.org/10.5455/ovj.2021.v11.i4.12
Medina I, Puicón V, Sandoval N. Frecuencia de Tumores en Piel de Caninos Diagnosticados Histopatológicamente en el Laboratorio de Patología Veterinaria de la Universidad Nacional Mayor de San Marcos (1999–2012). Rev Inv Vet Perú. 2017;28(2):448–454. https://doi.org/10.15381/rivep.v28i2.13065
Medina I. Frecuencia de tumores en piel de caninos diagnosticados histopatológicamente en el Laboratorio de Histología, Embriología y Patología Veterinaria de la UNMSM durante el periodo 1999- 2012 [Tesis]. Perú: Universidad Nacional Mayor De San Marcos; 2015. https://core.ac.uk/download/pdf/323345754.pdf
Meirelles AEWB, Oliveira EC, Rodrigues BA, Costa GR, Sonne L, Tesser ES, et al. Prevalência de neoplasmas cutâneos em cães da Região Metropolitana de Porto Alegre, RS: 1.017 casos (2002-2007). Pesq Vet Bras. 2010;30(11):968–973. https://doi.org/10.1590/S0100-736X2010001100011
Meuten DJ. Tumors in Domestic Animals. 5th Ed. Wiley-Blackwell; 2017. https://doi.org/10.1002/9781119181200
Millán Sepúlveda LF. Presentación de mastocitoma canino y neoplasias múltiples en un Golden Retriever. Un reporte de caso [Trabajo de grado]. Caldas: Corporación Universitaria Lasallista; 2021. https://repository.unilasallista.edu.co/items/81bdfdd4-7837-4662-9922-9eb80a5ccb35
Mochizuki H, Motsinger-Reif A, Bettini C, Moroff S, Breen M. Association of breed and histopathological grade in canine mast cell tumors. Vet Comp Oncol. 2017;15(3):829–839. https://doi.org/10.1111/vco.12225
North SM, Banks TA. Mast cell tumours. In: Small Animal Oncology: An Introduction. Elsevier; 2009. p. 183–196. https://doi.org/10.1016/B978-0-7020-2800-7.00023-6
O’Connell K, Thomson M. Evaluation of prognostic indicators in dogs with multiple, simultaneously occurring cutaneous mast cell tumors: 63 cases. Vet Comp Oncol. 2013;11(1):51–62. https://doi.org/10.1111/j.1476-5829.2011.00301.x
Patnaik AK, Ehler WJ, MacEwen EG. Canine Cutaneous Mast Cell Tumor: Morphologic Grading and Survival Time in 83 Dogs. Vet Pathol. 1984;21(5):469–474. https://doi.org/10.1177/030098588402100503
Reynolds BD, Thomson MJ, O’Connell K, Morgan EJ, Gummow B. Patient and tumor factors influencing canine mast cell tumor histological grade and mitotic index. Vet Comp Oncol. 2019;17(3):338–344. https://doi.org/10.1111/vco.12477
Rojas Parada DF. Revisión bibliográfica de mastocitoma en caninos [monografía de grado]. Villavicencio: Universidad de los Llanos, Facultad de Ciencias Agropecuarias y Recursos Naturales, Escuela de Ciencias Animales, Programa de Medicina Veterinaria; 2017. https://core.ac.uk/download/pdf/287326796.pdf
Shoop SJ, Marlow S, Church DB, English K, McGreevy PD, Stell AJ, et al. Prevalence and risk factors for mast cell tumours in dogs in England. Canine Genet Epidemiol. 2015;2:1-10. https://doi.org/10.1186/2052-6687-2-1
Simpson AM, Ludwig LL, Newman SJ, Bergman PJ, Hottinger HA & Patnaik AK. Evaluation of surgical margins required for complete excision of cutaneous mast cell tumors in dogs. JAVMA. 2004;224(2):236–240. https://doi.org/10.2460/javma.2004.224.236
Śmiech A, Lsopuszyński W, Ślaska B, Bulak K, Jasik A. Occurrence and distribution of canine cutaneous mast cell tumour characteristics among predisposed breeds. J Vet Res. 2019;63(1):141–148. https://doi.org/10.2478/jvetres-2019-0002
Śmiech A, Şlaska B, Łopuszyński W, Jasik A, Bochyńska D, Da¸browski R. Epidemiological assessment of the risk of canine mast cell tumours based on the Kiupel two-grade malignancy classification. Acta Vet Scand. 2018;60(70):1–9. https://doi.org/10.1186/s13028-018-0424-2
Śmiech A, Ślaska B, Surdyka M, Grzybowska-Szatkowska L, Łopuszyński W, Różańska D. Identification of additional mitochondrial DNA mutations in canine mast cell tumours. Acta Vet Scand. 2016;58(28):1-6. https://doi.org/10.1186/s13028-016-0210-y
Torres González-Chávez M, Fabré Rodríguez Y, Rodríguez Aurecochea JC, Calaña Seone L. Frecuencia de presentación de tumores cutáneos en caninos de la provincia La Habana entre 2009-2013. Rev Electron Vet. 2017;18(3):1-19. http://www.redalyc.org/articulo.oa?id=63651263004
Torres Vidales G, Eslava Mocha P. Mastocitoma canino. Orinoquia. 2006;10(2):45–51. https://www.redalyc.org/articulo.oa?id=89610206
Vicario C, Freixa N. Factores clínicos y patológicos importantes en el pronóstico del mastocitoma canino. Clin Vet Peq Anim. 2018;38(4):235–240. https://www.clinvetpeqanim.com/img/pdf/1534109958.pdf
Warland J & Dobson J. Breed predispositions in canine mast cell tumour: A single centre experience in the United Kingdom. The Veterinary Journal. 2013;197(2)496–498. http://dx.doi.org/10.1016/j.tvjl.2013.02.017
White CR, Hohenhaus AE, Kelsey J, Procter-Gray E. Cutaneous MCTs: Associations with Spay/Neuter Status, Breed, Body Size, and Phylogenetic Cluster. J Am Anim Hosp Assoc. 2011;47(3):210–216. https://doi.org/10.5326/jaaha-ms-5621
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Revista Colombiana de Ciencias Pecuarias
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The authors enable RCCP to reprint the material published in it.
The journal allows the author(s) to hold the copyright without restrictions, and will allow the author(s) to retain publishing rights without restrictions.
